Eptifibatide: gender related complications in a Hispanic population

One of the most common indications of Eptifibatide, a GP IIb/IIIa inhibitor, is non-ST segment elevation myocardial infarction (NSTEMI) due to its great antiplatelet activity. The aim of this study was to find out if there are gender discrepancies when comparing complications in Hispanics treated th Eptifibatide.

A cross-sectional study. 116 medical records with diagnosis ofNSTEMI managed with Eptifibatide during 2010-2012 were included. Bleeding, thrombocytopenia, new ischemia, anemia and death were variables compared.

The most common complication was death. There were four cases of bleeding, all of them occurred in the female gender, reaching a statistically significant difference compared to male gender (p = 0.0173); 8% of patients had thrombocytopenia; 9% had new ischemia during hospitalization; 13% died; 19% of patients developed anemia including the four cases of bleeding.

Bleeding occurred only in women, and this difference was statistically significant when compared to males. More studies emphasizing the differences in Eptifibatide complications by gender are needed. Furthermore, it would be important to compare these results to non-Hispanic women. The difference found in the other complications analyzed was not statistically significant.